MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

14.78 2.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.73

Максимум

14.88

Ключови измерители
By Trading Economics
Приходи	-23M -14M
Продажби	-22M 72M
Марж на печалбата	-18.944
Служители	624
EBITDA	-23M -6.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+40.85% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-829M 2B
Предишно отваряне	12.35
Предишно затваряне	14.78

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2026 г., 04:27 ч. UTC

Значими събития в новините

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5.04.2026 г., 23:55 ч. UTC

Пазарно говорене

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5.04.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.04.2026 г., 23:42 ч. UTC

Пазарно говорене

China's Consumer Inflation Likely Eased in March -- Market Talk

5.04.2026 г., 23:38 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5.04.2026 г., 12:57 ч. UTC

Значими събития в новините

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 18:30 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3.04.2026 г., 18:14 ч. UTC

Пазарно говорене

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3.04.2026 г., 17:50 ч. UTC

Пазарно говорене

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3.04.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3.04.2026 г., 16:50 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 16:12 ч. UTC

Печалби

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

3.04.2026 г., 15:20 ч. UTC

Значими събития в новините

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3.04.2026 г., 15:08 ч. UTC

Придобивния, сливания и поглъщания

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3.04.2026 г., 14:11 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3.04.2026 г., 12:56 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Meituan's Profitability Likely to Improve This Year -- Market Talk

3.04.2026 г., 07:45 ч. UTC

Пазарно говорене

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

40.85% нагоре

12-месечна прогноза

Среден 20.86 USD 40.85%

Висок 22 USD

Нисък 20 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.